TGTX

Over the past six months (April - October 2026), TG Therapeutics' stock was influenced by several events. The company reported Q1 2026 earnings with $201.3 million in product revenue and raised its full-year 2026 global revenue target to approximately $925 million. Q2 2026 financial results showed total global revenue of approximately $240 million, leading to a further increase in the full-year 2026 global revenue target to approximately $950 million, though Q2 earnings per share of $0.05 missed analyst estimates, causing an 11.26% share price drop. Other events included the completion of enrollment for the Phase 3 trial evaluating subcutaneous Briumvi in April 2026, with topline data expected around year-end 2026 or early 2027, and the announcement of its data schedule for MSToronto2026, including initial Phase 1 results for Azer-cel. The company also participated in investment conferences, a director sold 5,000 shares in September 2026, and the stock was influenced by broader market trends and positive analyst commentary on Briumvi's growth.